site stats

Spero therapeutics financial statements

WebSpero Therapeutics Working Capitalis quite stable at the moment as compared to the past year. The company's current value of Working Capitalis estimated at 2.28 Million. Spero … WebSPRO Spero Therapeutics Inc. Annual Income Statement - WSJ Spero Therapeutics Inc. SPRO (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EST 03/07/23 $1.69 USD …

Spero Therapeutics to Present Data at the 33rd European …

WebApr 10, 2024 · Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of . Spero … WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today … sixth season https://wrinfocus.com

SPERO THERAPEUTICS, INC. : Entry into a Material Definitive …

WebSep 30, 2024 · As of November 10, 2024, the registrant had 51,776,053shares of common stock, $0.001 par value per share, outstanding. Forward-Looking STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that … WebApr 6, 2024 · Spero Therapeutics, Inc. (NASDAQ: SPRO) Q4 2024 Earnings Call Transcript March 30, 2024 Operator: Good afternoon, and welcome to Spero Therapeutics Fourth … WebJun 30, 2024 · Item 1.01 Entry into a Material Definitive Agreement. On June 30, 2024, Spero Therapeutics, Inc. (the "Company") entered into a license agreement (the "License Agreement") with Pfizer Inc. ("Pfizer").. Pursuant to the License Agreement, the Company has granted Pfizer the rights to develop, manufacture, and commercialize the Company's … sushi pop wirt

Spero Therapeutics to Present Data at the 33rd European …

Category:SPRO - Spero Therapeutics Stock Financial Summary - Barchart.com

Tags:Spero therapeutics financial statements

Spero therapeutics financial statements

Spero Therapeutics to Present Data at the 33rd European …

WebOn June 4, 2024, Spero Therapeutics, Inc. (the “Company”) updated its investor presentation (the “Investor Presentation”), which the Company expects to use in connection with general corporate presentations and will be made available on the Company’s website or distributed by the Company in hardcopy or electronic form. Websending a written request to: Spero Therapeutics, Inc., Attn: Investor Relations, 675 Massachusetts Avenue, 14thFloor, Cambridge, Massachusetts 02139. Exhibits will be provided upon written request and payment of an appropriate processing fee. Table of Contents IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

Spero therapeutics financial statements

Did you know?

WebDec 31, 2024 · As of December 31, 2024, we had federal and state net operating loss carryforwards of $291.9 million and $282.9 million , respectively, which may be available to offset future income tax liabilities. The federal NOLs of $73.0 million will expire at various dates from 2033 to 2037 and approximately $218.9 million can be carried forward … WebApr 14, 2024 · Spero Therapeutics’ ECCMID 2024 scientific exchange submissions can be found at Key Publications and Presentations on the Spero Therapeutics corporate website. These research and poster ...

WebMay 3, 2024 · CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and... WebMay 4, 2024 · Spero shares soon peaked at about $22 apiece as the company began plans to seek regulatory approval. The FDA accepted its application on Jan. 3. However, almost all of Spero's market value has …

WebSpero Therapeutics financials statements overview reports - balance sheet, income statement, cash flow, earnings & estimates, ratio, and margins. View [DE:2HA] financial … Web1 day ago · Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 …

WebApr 14, 2024 · However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. Investor Relations Contact: Ted Jenkins

sixth science ncert bookWebSpero Therapeutics Inc. Annual stock financials by MarketWatch. View the latest SPRO financial statements, income statements and financial ratios. sixth scienceWebSpero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused ... sushi pop yelpWebSpero Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income The reasoning behind the adjustment, however, is that … sixth sealWebSPRO Spero Therapeutics Inc. Quarterly Income Statement - WSJ Spero Therapeutics Inc. SPRO (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EDT 04/06/23 $1.51 USD 0.06 4.14% AFTER... sixth seal news talkWebMar 30, 2024 · In connection with Spero's license agreement with GSK, and pursuant to a stock purchase agreement, Spero received a $9 million equity investment from GSK, in November 2024, with GSK purchasing... sixth science second term bookWebMar 22, 2024 · Spero Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.106; its P/E ratio is -0.45; Spero Therapeutics is scheduled to report earnings on … sushi porcelain set